Abstract:Breast cancer is one of the major impediments affecting women globally. The ATP-dependant heat shock protein 90 (Hsp90) forms the central component of molecular chaperone machinery that predominantly governs the folding of newly synthesized peptides and their conformational maturation. It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer. In the present in silico investigation, a structure-based pharmacophore model was generated with hydrogen bond donor, hydrogen bond acceptor and hydrophobic features complementary to crucial residues Ala55, Lys58, Asp93, Ile96, Met98 and Thr184 directed at inhibiting the ATP-binding activity of Hsp90. Subsequently, the phytochemical dataset of 3210 natural compounds was screened to retrieve the prospective inhibitors after rigorous validation of the model pharmacophore. The retrieved 135 phytocompounds were further filtered by drug-likeness parameters including Lipinski's rule of five and ADMET properties, then investigated via molecular docking-based scoring. Molecular interactions were assessed using Genetic Optimisation for Ligand Docking program for 95 drug-like natural compounds against Hsp90 along with two clinical drugs as reference compounds - Geldanamycin and Radicicol. Docking studies revealed three phytochemicals are better than the investigated clinical drugs. The reference and hit compounds with dock scores of 48.27 (Geldanamycin), 40.90 (Radicicol), 73.04 (Hit1), 72.92 (Hit2) and 68.12 (Hit3) were further validated for their binding stability through molecular dynamics simulations. We propose that the non-macrocyclic scaffolds of three identified phytochemicals might aid in the development of novel therapeutic candidates against Hsp90-driven cancers.

Dual-Targeted Drug Design Of Her2 And Hsp90 By Comfa Model And Pharmacophore Analysis

Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors

Structure-based and ligand-based drug design for HER 2 receptor.

What is the Key Point for Designing HER2 Inhibitors?

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Screening from Tcm Database@Taiwan and Qsar Model for Identifying Her2 Inhibitors

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation

Insight into the structural and dynamic properties of novel HSP90 inhibitors through DFT calculations and molecular dynamics simulations

Synthesis of C3′‐Foused Aryl/Penta‐1,4‐dien‐3‐one/Amine Hybrids as HSP90 C‐Terminal Inhibitors

Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods

Pharmacophore Model Analysis Of Novel Tyrphostins

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.

Structure-Aware Dual-Target Drug Design through Collaborative Learning of Pharmacophore Combination and Molecular Simulation

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Artificial Intelligence Approach to Find Lead Compounds for Treating Tumors

Structural aspects of triazole derivatives as HSP90 inhibitors for the treatment of cancer: in silico studies

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.